Sanderling Ventures

Pulsar Vascular Intra Aneursym Implant

Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies We demonstrate that significant companies are best built in close working partnerships with entrepreneurs

HOW WE CAN HELP

Our unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates of return for both its entrepreneurs and investors

Small molecule therapeutics Biologics and vaccines Drug delivery Platform technologies Medical devices

January 9, 2023 - Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG

November 21, 2022 - Graybug and CalciMedica Enter into Definitive Merger Agreement

July 11, 2022 - Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes